AU · rank #19 · 2026-10-22
SRT3
XETRA · EUR · $21.09B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.028 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.02 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $273.63 | +4.8% |
| Momentum acceleration 3-month minus 12-month momentum. | +15.81% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.21 |
| Gross margin TTM | +45.7% |
| 52w high | $272.50 |
| Market cap (USD) | $21.09B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Sartorius Aktiengesellschaft provides integrated bioprocessing equipment and recurring single-use consumables, including filtration systems, bioreactors, and laboratory instruments for biopharmaceutical manufacturing [1].
Rationale
Reaffirmed full-year 2026 sales growth guidance of 5–9% and H1 operational revenue expansion of 7.7% validate the model's 70% analyst revision agreement and positive rating momentum [1].
Material risks
- 1Direct product substitutability by peers like Danaher, Thermo Fisher, and Merck without named order backlog protection exposes Sartorius to pricing pressure and customer share shifts [1].
- 2High leverage at 3.51x net debt-to-EBITDA combined with ongoing tariff compensation costs creates balance sheet and cash flow vulnerability [1].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.